Differential serological and neutralizing antibody dynamics after an infection by a single SARS-CoV-2 strain.


Journal

Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307

Informations de publication

Date de publication:
Aug 2021
Historique:
received: 12 09 2020
accepted: 10 11 2020
pubmed: 3 1 2021
medline: 19 8 2021
entrez: 2 1 2021
Statut: ppublish

Résumé

We report here the case of two coworkers infected by the same SARS-CoV-2 strain, presenting two different immunological outcomes. One patient presented a strong IgG anti-receptor-binding domain immune response correlated with a low and rapidly decreasing titer of neutralizing antibodies. The other patient had a similar strong IgG anti-receptor-binding domain immune response but high neutralizing antibody titers. Thus, host individual factors may be the main drivers of the immune response varying with age and clinical severity.

Sections du résumé

BACKGROUND BACKGROUND
We report here the case of two coworkers infected by the same SARS-CoV-2 strain, presenting two different immunological outcomes.
CASE METHODS
One patient presented a strong IgG anti-receptor-binding domain immune response correlated with a low and rapidly decreasing titer of neutralizing antibodies. The other patient had a similar strong IgG anti-receptor-binding domain immune response but high neutralizing antibody titers.
DISCUSSION AND CONCLUSION CONCLUSIONS
Thus, host individual factors may be the main drivers of the immune response varying with age and clinical severity.

Identifiants

pubmed: 33387262
doi: 10.1007/s15010-020-01556-8
pii: 10.1007/s15010-020-01556-8
pmc: PMC7776280
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
Immunoglobulin G 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

781-783

Subventions

Organisme : Délégation Générale pour l'Armement
ID : Biomedef COVID 5

Informations de copyright

© 2021. Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Morens DM, Daszak P, Markel H, Taubenberger JK. Pandemic COVID-19 joins history’s pandemic legion. mBio. 2020;11:3.
Vabret N, Britton GJ, Gruber C, et al. Immunology of COVID-19: current state of the science. Immunity. 2020;52:910–41.
doi: 10.1016/j.immuni.2020.05.002
Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26:845–8.
doi: 10.1038/s41591-020-0897-1
To KKW, Tsang OTY, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20:565–74.
doi: 10.1016/S1473-3099(20)30196-1
Jiang S, Hillyer C, Du L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol. 2020;41:355–9.
doi: 10.1016/j.it.2020.03.007
Okba NMA, Muller MA, Li W, et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients. Emerg Infect Dis. 2020;26:1478–88.
doi: 10.3201/eid2607.200841
Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581:465–9.
doi: 10.1038/s41586-020-2196-x
Quick J, Grubaugh ND, Pullan ST, et al. Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples. Nat Protoc. 2017;12:1261–76.
doi: 10.1038/nprot.2017.066
Gambaro F, Behillil S, Baidaliuk A, et al. Introductions and early spread of SARS-CoV-2 in France, 24 January to 23 March 2020. Euro Surveill. 2020;25:26.
doi: 10.2807/1560-7917.ES.2020.25.26.2001200
Korber B, Fischer WM, Gnanakaran S, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182:812–27.
doi: 10.1016/j.cell.2020.06.043
Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020;26:1033–6.
doi: 10.1038/s41591-020-0913-5
Yuan M, Wu NC, Zhu X, et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science. 2020;368:630–3.
doi: 10.1126/science.abb7269
Ju B, Zhang Q, Ge J, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020;584:115–9.
doi: 10.1038/s41586-020-2380-z
Wang X, Guo X, Xin Q, et al. Neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 in coronavirus disease 2019 inpatients and convalescent patients. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa721
doi: 10.1093/cid/ciaa721 pubmed: 33383587 pmcid: 7717201
Park MD. Sex differences in immune responses in COVID-19. Nature Rev Immunol. 2020;20:461.
doi: 10.1038/s41577-020-0378-2

Auteurs

Emmanuelle Billon-Denis (E)

Microbiology and Infectious Diseases Department, Institut de Recherche Biomédicale des Armées (IRBA), 1 place Général Valérie André, 91220, Brétigny sur Orge, France.
Institut Pasteur, Innovative Vaccine Laboratory, Paris, France.

Audrey Ferrier-Rembert (A)

Microbiology and Infectious Diseases Department, Institut de Recherche Biomédicale des Armées (IRBA), 1 place Général Valérie André, 91220, Brétigny sur Orge, France.

Annabelle Garnier (A)

Microbiology and Infectious Diseases Department, Institut de Recherche Biomédicale des Armées (IRBA), 1 place Général Valérie André, 91220, Brétigny sur Orge, France.

Laurence Cheutin (L)

Microbiology and Infectious Diseases Department, Institut de Recherche Biomédicale des Armées (IRBA), 1 place Général Valérie André, 91220, Brétigny sur Orge, France.

Clarisse Vigne (C)

Microbiology and Infectious Diseases Department, Institut de Recherche Biomédicale des Armées (IRBA), 1 place Général Valérie André, 91220, Brétigny sur Orge, France.

Emilie Tessier (E)

Microbiology and Infectious Diseases Department, Institut de Recherche Biomédicale des Armées (IRBA), 1 place Général Valérie André, 91220, Brétigny sur Orge, France.

Jessica Denis (J)

Microbiology and Infectious Diseases Department, Institut de Recherche Biomédicale des Armées (IRBA), 1 place Général Valérie André, 91220, Brétigny sur Orge, France.

Cyril Badaut (C)

Microbiology and Infectious Diseases Department, Institut de Recherche Biomédicale des Armées (IRBA), 1 place Général Valérie André, 91220, Brétigny sur Orge, France.

Clémence Rougeaux (C)

Microbiology and Infectious Diseases Department, Institut de Recherche Biomédicale des Armées (IRBA), 1 place Général Valérie André, 91220, Brétigny sur Orge, France.

Anne Depeille Wuille (A)

Microbiology and Infectious Diseases Department, Institut de Recherche Biomédicale des Armées (IRBA), 1 place Général Valérie André, 91220, Brétigny sur Orge, France.

Hawa Timera (H)

Microbiology and Infectious Diseases Department, Institut de Recherche Biomédicale des Armées (IRBA), 1 place Général Valérie André, 91220, Brétigny sur Orge, France.

Laet Itia Boutin (LI)

Microbiology and Infectious Diseases Department, Institut de Recherche Biomédicale des Armées (IRBA), 1 place Général Valérie André, 91220, Brétigny sur Orge, France.

Isabelle Drouet (I)

Microbiology and Infectious Diseases Department, Institut de Recherche Biomédicale des Armées (IRBA), 1 place Général Valérie André, 91220, Brétigny sur Orge, France.

Noémie Verguet (N)

Microbiology and Infectious Diseases Department, Institut de Recherche Biomédicale des Armées (IRBA), 1 place Général Valérie André, 91220, Brétigny sur Orge, France.

Flora Nolent (F)

Microbiology and Infectious Diseases Department, Institut de Recherche Biomédicale des Armées (IRBA), 1 place Général Valérie André, 91220, Brétigny sur Orge, France.

Olivier Gorgé (O)

Microbiology and Infectious Diseases Department, Institut de Recherche Biomédicale des Armées (IRBA), 1 place Général Valérie André, 91220, Brétigny sur Orge, France.

Olivier Ferraris (O)

Microbiology and Infectious Diseases Department, Institut de Recherche Biomédicale des Armées (IRBA), 1 place Général Valérie André, 91220, Brétigny sur Orge, France.

Jean-Nicolas Tournier (JN)

Microbiology and Infectious Diseases Department, Institut de Recherche Biomédicale des Armées (IRBA), 1 place Général Valérie André, 91220, Brétigny sur Orge, France. jean-nicolas.tournier@intradef.gouv.fr.
Institut Pasteur, Innovative Vaccine Laboratory, Paris, France. jean-nicolas.tournier@intradef.gouv.fr.
Ecole du Val-de-Grâce, Paris, France. jean-nicolas.tournier@intradef.gouv.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH